HYDERABAD: Hyderabad-based pharma player Suven Life Sciences Ltd (Suven) on Thursday informed the bourses that it has secured one product patent each from Canada, Europe and Hong Kong.
“Suven has been granted one product patent each from Canada (2785838), Europe (2888243) and Hong Kong (HK 1187340) corresponding to new chemical entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases and these patents are valid through 2030, 2032 and 2032 respectively,” the company informed the bourses.
According to the company, products developed out of these inventions may be out-licenced during various phases of clinical development
Commenting on the development, Suven chief executive officer Venkat Jasti said, “We are very pleased by the grant of these patents for our pipeline of molecules in the CNS arena that are being developed for cognitive disorders with high unmet medical needs and huge market potential globally.”
[Source:-Times Of India]
